Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

A Data Center Developer Is Paying Kansas Households $1,000 a Year for a Decade, Which Is About $83 a Month

by Team Lumida
10 hours ago
A Data Center Developer Is Paying Kansas Households $1,000 a Year for a Decade, Which Is About $83 a Month

The project covers 1,400 acres and will support 250 permanent jobs. Community payments are becoming a standard development cost.

Read more

ASML Raises 2026 Guidance to €44-45bn; Cannot Fully Meet 2027-2028 Demand; Multi-Year Forward Orders Extend to 2029-2030, Validating Sustained AI Capex Cycle

by Team Lumida
19 hours ago
ASML Raises 2026 Guidance to €44-45bn; Cannot Fully Meet 2027-2028 Demand; Multi-Year Forward Orders Extend to 2029-2030, Validating Sustained AI Capex Cycle

ASML Q3: €11.66bn revenue; raised 2026 to €44-45bn. Cannot meet 2027-2028 demand with current plans; investigating >30% capacity increase. CEO Fouquet: 'customers asking daily for more tools.' Customers...

Read more

Nvidia Adds $2 Billion to Europe While Funding a Startup Whose Own Valuation Fell 38%

by Team Lumida
1 day ago
Nvidia Adds $2 Billion to Europe While Funding a Startup Whose Own Valuation Fell 38%

Huang and Alibaba's chairman are now giving Europe identical advice on open models. Both sell into the answer.

Read more

SpaceX Agrees to NYC Council AI Safety Testimony After Subpoena Threat; Musk-Backed Grok Testifies Friday as Deepfake Porn Lawsuits Mount and Federal Agencies Question Pentagon Usage

by Team Lumida
2 days ago
SpaceX Agrees to NYC Council AI Safety Testimony After Subpoena Threat; Musk-Backed Grok Testifies Friday as Deepfake Porn Lawsuits Mount and Federal Agencies Question Pentagon Usage

SpaceX testifying Fri (Oct 18) 10 AM to NYC Council tech committee. Originally subpoenaed Sept 28 for Oct 5 hearing; skipped. Anthropic, OpenAI, Google, Meta testified Oct 5....

Read more

Meta’s Muse Wonder Reaches AI Frontier, Zuckerberg Commits to Further Vast Spending; Stock Up 10% Since Muse Launch Despite Amazon Throttling Agents and Privacy Concerns

by Team Lumida
2 days ago
Meta’s Muse Wonder Reaches AI Frontier, Zuckerberg Commits to Further Vast Spending; Stock Up 10% Since Muse Launch Despite Amazon Throttling Agents and Privacy Concerns

Meta released Muse Wonder; Zuckerberg: at AI 'frontier.' Outperforms Claude Opus 5.5, GPT-6 Astra on benchmarks. Muse app most-downloaded US both platforms. Stock +10% since Sept. $1.8T company....

Read more

China’s AI Chip Self-Sufficiency Dream Derailed; 1 Million+ Nvidia Workaround Purchases Expose Supply Shortfall as Domestic Demand Outpaces Output Through 2030

by Team Lumida
2 days ago
Apollo’s Torsten Slok Warns AI Agents Could Trigger Slow-Motion Bank Run; Muse + Agentic AI Auto-Sweeping Deposits 0.1% → 5%; $7.78B Market 2026, $43.52B By 2031; x402 Protocol 188M+ Transactions

China bought 1M+ Nvidia gaming/workstation chips (RTX Pro) this year as workaround. Supply 3.5M vs demand >5M. 2027: demand could exceed 10M vs production 5M+. CUDA lock-in real;...

Read more

Tencent Raises $5 Billion in Bonds for AI Capex as Chinese Tech Giants Fund Competitive Arms Race; Annual Spending to Exceed 200 Billion Yuan Through 2027

by Team Lumida
3 days ago
Tencent Raises $5 Billion in Bonds for AI Capex as Chinese Tech Giants Fund Competitive Arms Race; Annual Spending to Exceed 200 Billion Yuan Through 2027

Tencent raising $5B bonds ($1.5-2B USD + 20-25B yuan offshore). Proceeds for AI capex (bulk for chip purchases). Q2 capex 52.8B yuan (176% YoY growth). Annual spending >200B...

Read more

Intel and Broadcom CEOs Warn Capital Crunch Could Surpass Chip Shortages as AI’s Biggest Constraint; Rising Bond Yields Threaten Data Center Economics

by Team Lumida
3 days ago
Intel Surges 5%, SK Hynix Up 3% on Reports of U.S. Memory Chip Manufacturing Deal to Serve Nvidia and AI Demand

Broadcom CEO Hock Tan says capital access may be bigger constraint than chip/memory shortages. Intel CEO Lip-Bu Tan cites rising cost of capital and ROI questions. Supply bottlenecks...

Read more

SoftBank’s Masayoshi Son Hunts $100 Billion from Gulf Investors to Scale AI Bets as OpenAI IPO Delays and Valuation Concerns Mount

by Team Lumida
6 days ago
SoftBank Bets Big on AI: Ditches $15bn Buyback Plan Despite Investor Pressure

SoftBank founder seeks up to $100B from UAE and Saudi Arabia to fund AI expansion. Son would use capital to acquire companies and improve them with AI. Comes...

Read more

Isomorphic Labs Series C at $40-50B Valuation — Alphabet’s AI Drug Discovery Spinoff Attracts International Capital as Application Layer Commands Premium While Infrastructure Investors Retreat

by Team Lumida
7 days ago
Isomorphic Labs Series C at $40-50B Valuation — Alphabet’s AI Drug Discovery Spinoff Attracts International Capital as Application Layer Commands Premium While Infrastructure Investors Retreat

Isomorphic Labs (Google DeepMind spinoff) raising Series C at $40-50B valuation (vs $2.1B Series B 5mo ago). Eli Lilly, Novartis partnerships. Demis Hassabis: cut drug discovery years to...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Trump Pushes for Greenland Acquisition, Exploring Business Deals and Military Presence

Senate Backs Trump’s Iran War Authority After War-Powers Challenge Fails

March 5, 2026
Robinhood Eyes Crypto Futures Expansion in US and Europe

Robinhood Eyes Crypto Futures Expansion in US and Europe

July 3, 2024
gold and black metal tool

Gold Trading Talent War Heats Up as Bullion Boom Drives Hiring and Pay Surges

October 27, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018